<?xml version='1.0' encoding='utf-8'?>
<document id="19637945"><sentence text="Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives."><entity charOffset="18-47" id="DDI-PubMed.19637945.s1.e0" text="tenofovir disoproxil fumarate" /></sentence><sentence text="To assess the potential for a drug-drug interaction between a representative hormonal contraceptive (norgestimate-ethinyl estradiol) and tenofovir disoproxil fumarate (tenofovir DF), a prodrug of tenofovir, when coadministered"><entity charOffset="114-131" id="DDI-PubMed.19637945.s2.e0" text="ethinyl estradiol" /><entity charOffset="137-166" id="DDI-PubMed.19637945.s2.e1" text="tenofovir disoproxil fumarate" /><entity charOffset="168-180" id="DDI-PubMed.19637945.s2.e2" text="tenofovir DF" /><entity charOffset="196-205" id="DDI-PubMed.19637945.s2.e3" text="tenofovir" /><pair ddi="false" e1="DDI-PubMed.19637945.s2.e0" e2="DDI-PubMed.19637945.s2.e0" /><pair ddi="false" e1="DDI-PubMed.19637945.s2.e0" e2="DDI-PubMed.19637945.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19637945.s2.e0" e2="DDI-PubMed.19637945.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19637945.s2.e0" e2="DDI-PubMed.19637945.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19637945.s2.e1" e2="DDI-PubMed.19637945.s2.e1" /><pair ddi="false" e1="DDI-PubMed.19637945.s2.e1" e2="DDI-PubMed.19637945.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19637945.s2.e1" e2="DDI-PubMed.19637945.s2.e3" /><pair ddi="false" e1="DDI-PubMed.19637945.s2.e2" e2="DDI-PubMed.19637945.s2.e2" /><pair ddi="false" e1="DDI-PubMed.19637945.s2.e2" e2="DDI-PubMed.19637945.s2.e3" /></sentence><sentence text="" /><sentence text="Thirty-day, open-label, fixed-sequence, pharmacokinetic drug-drug interaction study" /><sentence text="" /><sentence text="Single clinical phase I center" /><sentence text="" /><sentence text="Twenty nonpregnant and nonlactating women aged 19-45 years who were taking a norgestimate-ethinyl estradiol oral contraceptive"><entity charOffset="90-107" id="DDI-PubMed.19637945.s8.e0" text="ethinyl estradiol" /></sentence><sentence text="" /><sentence text="Each woman received norgestimate-ethinyl estradiol alone on study days 1-22, followed by norgestimate-ethinyl estradiol plus tenofovir DF 300 mg once/day for 7 days during two consecutive 28-day contraceptive cycles"><entity charOffset="33-50" id="DDI-PubMed.19637945.s10.e0" text="ethinyl estradiol" /><entity charOffset="102-119" id="DDI-PubMed.19637945.s10.e1" text="ethinyl estradiol" /><entity charOffset="125-134" id="DDI-PubMed.19637945.s10.e2" text="tenofovir" /><pair ddi="false" e1="DDI-PubMed.19637945.s10.e0" e2="DDI-PubMed.19637945.s10.e0" /><pair ddi="false" e1="DDI-PubMed.19637945.s10.e0" e2="DDI-PubMed.19637945.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19637945.s10.e0" e2="DDI-PubMed.19637945.s10.e2" /><pair ddi="false" e1="DDI-PubMed.19637945.s10.e1" e2="DDI-PubMed.19637945.s10.e1" /><pair ddi="false" e1="DDI-PubMed.19637945.s10.e1" e2="DDI-PubMed.19637945.s10.e2" /></sentence><sentence text="" /><sentence text="Pharmacokinetic assessments were performed over 24 hours on study days 1 and 29 (corresponding to matching days [day 21] of the two contraceptive cycles)" /><sentence text=" Serum or plasma concentrations of tenofovir, norgestimate and its active metabolite deacetyl norgestimate, and ethinyl estradiol were measured by high-performance liquid chromatography-tandem mass spectrometry assays"><entity charOffset="35-44" id="DDI-PubMed.19637945.s13.e0" text="tenofovir" /><entity charOffset="46-58" id="DDI-PubMed.19637945.s13.e1" text="norgestimate" /><entity charOffset="85-106" id="DDI-PubMed.19637945.s13.e2" text="deacetyl norgestimate" /><entity charOffset="112-129" id="DDI-PubMed.19637945.s13.e3" text="ethinyl estradiol" /><pair ddi="false" e1="DDI-PubMed.19637945.s13.e0" e2="DDI-PubMed.19637945.s13.e0" /><pair ddi="false" e1="DDI-PubMed.19637945.s13.e0" e2="DDI-PubMed.19637945.s13.e1" /><pair ddi="false" e1="DDI-PubMed.19637945.s13.e0" e2="DDI-PubMed.19637945.s13.e2" /><pair ddi="false" e1="DDI-PubMed.19637945.s13.e0" e2="DDI-PubMed.19637945.s13.e3" /><pair ddi="false" e1="DDI-PubMed.19637945.s13.e1" e2="DDI-PubMed.19637945.s13.e1" /><pair ddi="false" e1="DDI-PubMed.19637945.s13.e1" e2="DDI-PubMed.19637945.s13.e2" /><pair ddi="false" e1="DDI-PubMed.19637945.s13.e1" e2="DDI-PubMed.19637945.s13.e3" /><pair ddi="false" e1="DDI-PubMed.19637945.s13.e2" e2="DDI-PubMed.19637945.s13.e2" /><pair ddi="false" e1="DDI-PubMed.19637945.s13.e2" e2="DDI-PubMed.19637945.s13.e3" /></sentence><sentence text=" Geometric mean ratios (90% confidence intervals) for the pharmacokinetic parameters for deacetyl norgestimate and ethinyl estradiol were estimated by using analysis of variance and compared with the no-effect criterion for bioequivalence"><entity charOffset="89-110" id="DDI-PubMed.19637945.s14.e0" text="deacetyl norgestimate" /><entity charOffset="115-132" id="DDI-PubMed.19637945.s14.e1" text="ethinyl estradiol" /><pair ddi="false" e1="DDI-PubMed.19637945.s14.e0" e2="DDI-PubMed.19637945.s14.e0" /><pair ddi="false" e1="DDI-PubMed.19637945.s14.e0" e2="DDI-PubMed.19637945.s14.e1" /></sentence><sentence text=" The tenofovir pharmacokinetic parameters were compared with historical controls"><entity charOffset="5-14" id="DDI-PubMed.19637945.s15.e0" text="tenofovir" /></sentence><sentence text=" Pharmacokinetic parameters for deacetyl norgestimate and ethinyl estradiol were unaltered by coadministration of tenofovir DF"><entity charOffset="32-53" id="DDI-PubMed.19637945.s16.e0" text="deacetyl norgestimate" /><entity charOffset="58-75" id="DDI-PubMed.19637945.s16.e1" text="ethinyl estradiol" /><entity charOffset="114-123" id="DDI-PubMed.19637945.s16.e2" text="tenofovir" /><pair ddi="false" e1="DDI-PubMed.19637945.s16.e0" e2="DDI-PubMed.19637945.s16.e0" /><pair ddi="false" e1="DDI-PubMed.19637945.s16.e0" e2="DDI-PubMed.19637945.s16.e1" /><pair ddi="false" e1="DDI-PubMed.19637945.s16.e0" e2="DDI-PubMed.19637945.s16.e2" /><pair ddi="false" e1="DDI-PubMed.19637945.s16.e1" e2="DDI-PubMed.19637945.s16.e1" /><pair ddi="false" e1="DDI-PubMed.19637945.s16.e1" e2="DDI-PubMed.19637945.s16.e2" /></sentence><sentence text=" The tenofovir pharmacokinetic parameters in subjects receiving norgestimate-ethinyl estradiol were consistent with historical control data for tenofovir"><entity charOffset="5-14" id="DDI-PubMed.19637945.s17.e0" text="tenofovir" /><entity charOffset="77-94" id="DDI-PubMed.19637945.s17.e1" text="ethinyl estradiol" /><pair ddi="false" e1="DDI-PubMed.19637945.s17.e0" e2="DDI-PubMed.19637945.s17.e0" /><pair ddi="false" e1="DDI-PubMed.19637945.s17.e0" e2="DDI-PubMed.19637945.s17.e1" /></sentence><sentence text="" /><sentence text="Tenofovir DF and norgestimate-ethinyl estradiol are not involved in a clinically significant drug-drug interaction; tenofovir DF did not affect the steady-state pharmacokinetics of norgestimate or ethinyl estradiol, including the concentration at the end of the dosing interval"><entity charOffset="0-9" id="DDI-PubMed.19637945.s19.e0" text="Tenofovir" /><entity charOffset="17-29" id="DDI-PubMed.19637945.s19.e1" text="norgestimate" /><entity charOffset="30-47" id="DDI-PubMed.19637945.s19.e2" text="ethinyl estradiol" /><entity charOffset="116-125" id="DDI-PubMed.19637945.s19.e3" text="tenofovir" /><entity charOffset="181-193" id="DDI-PubMed.19637945.s19.e4" text="norgestimate" /><entity charOffset="197-214" id="DDI-PubMed.19637945.s19.e5" text="ethinyl estradiol" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e0" e2="DDI-PubMed.19637945.s19.e0" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e0" e2="DDI-PubMed.19637945.s19.e1" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e0" e2="DDI-PubMed.19637945.s19.e2" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e0" e2="DDI-PubMed.19637945.s19.e3" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e0" e2="DDI-PubMed.19637945.s19.e4" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e0" e2="DDI-PubMed.19637945.s19.e5" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e1" e2="DDI-PubMed.19637945.s19.e1" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e1" e2="DDI-PubMed.19637945.s19.e2" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e1" e2="DDI-PubMed.19637945.s19.e3" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e1" e2="DDI-PubMed.19637945.s19.e4" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e1" e2="DDI-PubMed.19637945.s19.e5" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e2" e2="DDI-PubMed.19637945.s19.e2" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e2" e2="DDI-PubMed.19637945.s19.e3" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e2" e2="DDI-PubMed.19637945.s19.e4" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e2" e2="DDI-PubMed.19637945.s19.e5" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e3" e2="DDI-PubMed.19637945.s19.e3" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e3" e2="DDI-PubMed.19637945.s19.e4" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e3" e2="DDI-PubMed.19637945.s19.e5" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e4" e2="DDI-PubMed.19637945.s19.e4" /><pair ddi="false" e1="DDI-PubMed.19637945.s19.e4" e2="DDI-PubMed.19637945.s19.e5" /></sentence><sentence text=" Both drugs were well tolerated when coadministered" /><sentence text=" Tenofovir DF is unlikely to affect the pharmacokinetics of hormonal oral contraceptives" /><sentence text="" /></document>